|
|
Ahmet |
|
C. Berkyurek |
|
CEO & Co-founder |
CamMed Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/10/Ahmet-Berkyurek.jpg |
Dr. Berkyurek is the co-founder and Chief Executive Officer (CEO) of CamMed, and completed M.Sc. and Ph.D. degrees at Osaka University with a research fellowship from the Japanese Government, and a B.Sc. degree from Istanbul Technical University (ITU). Dr. Berkyurek continued his scientific career at the University of Cambridge as a research fellow with a Marie-Curie Fellowship in the area of RNA Biology, and worked in the biotech industry at the intersection of biochemistry, cell biology, RNA biology, oligonucleotide and vaccine/RNA therapeutics. Dr. Berkyurek has been nominated as a finalist in the category of Researcher of the Year 2023 by Cambridge Independent Science and Technology Awards for his discoveries in RNA therapeutics to prevent SARS-CoV-2 infections. |
|
|
Alan |
|
Palmer |
|
Chief Executive Officer |
Elixa MediScience |
https://proventainternational.com/wp-content/uploads/2025/09/Alan-parmer.png |
|
|
|
Ameet |
|
Ambarkhane |
|
CDO |
Halo Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/10/Ameet_Ambarkhane_square_optimized.jpg |
Dr. Ameet Ambarkhane is a translational R&D executive with extensive experience advancing programs from hit triage to clinical development across global pharma and agile biotech ventures. At Novartis, he steered cross-functional lead-optimization teams across DMPK, safety, biology, medicinal chemistry, and developability—delivering multiple NMEs into GLP toxicology and advancing candidates through clinical Proof-of-Concept. His therapeutic breadth covers small molecules, recombinant proteins, and nucleic acid modalities. Recently, as CDO at Halo Therapeutics, Ameet led metabolic GPCR programs targeting incretin pathways via biased signalling mechanism. He focused on incorporating workflows for building integrated discovery engines that connect design with wet-lab DMTA cycles and governed CRO networks to accelerate lead nomination and clinical entry. |
|
|
Amit |
|
Nayyar |
|
Senior Director |
XtalPi Inc. |
https://proventainternational.com/wp-content/uploads/2026/10/Amit-Nayyar.jpg |
Amit Nayyar, PhD is Senior Director, Chemistry Platform, Automation and AI at XtalPi. He is a scientific leader with more than 20 years of global experience in drug discovery and development, preclinical R&D, and business development across the pharmaceutical, biotechnology, and CDMO industries. His expertise spans small molecules, antibody-drug conjugates (ADCs), peptides, peptide-drug conjugates (PDCs), and oligonucleotide therapeutics, with a strong emphasis on applying AI, automation, and advanced technologies to accelerate research and development. Prior to joining XtalPi, Dr. Nayyar held leadership positions at Cohance Life Sciences, Theratechnologies, Paraza Pharma, AstraZeneca, Dr. Reddy’s Laboratories, and Curia. Earlier in his career, he worked at the Tuberculosis Research Section (TRS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), where he contributed to the discovery and development PretomanidTM, a globally approved treatment for drug-resistant tuberculosis. Dr. Nayyar holds a PhD in Medicinal Chemistry and is an inventor on seven patents and author of 18 peer-reviewed scientific publications. He serves as a reviewer for international scientific journals and has been an invited speaker, moderator, and panelist at numerous global conferences, where he shares insights on medicinal chemistry, drug discovery, targete |
|
|
Avinash |
|
Patel |
|
Vice President and Head of Early Discovery |
Dewpoint Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/08/Avinash-Patel.jpg |
I am a discovery leader who builds platforms, teams, and partnerships that turn complex biology into real drug programs.
Over the past several years, I have been leading global teams across the US and Europe, working closely with big pharma partners to deliver high-impact discovery programs and aggressive revenue-generating milestones. I’m comfortable operating in complex stakeholder environments and aligning science, strategy, and execution to move programs forward.
My work sits at the intersection of functional genomics, phenotypic biology, and AI/ML. I focus on defining the right biological problems – the ones where data, scale, and computation genuinely improve the odds of success. I have built genome-wide CRISPR and phenotypic discovery platforms that now fuel both internal pipelines and major pharma collaborations.
I’m known for creative problem solving, especially in areas others consider “undruggable.” As a thought leader in biomolecular condensates, I’ve helped shape the field while translating that science into scalable drug discovery engines across diabetes, obesity, cardiovascular disease, and oncology.
I build high-performing teams. I build platforms that last. And I build partnerships that deliver. |
|
|
Levente |
|
Meszaros |
|
Vice President Preclinical and Translational Science |
Radiopharm Theranostics |
https://proventainternational.com/wp-content/uploads/2026/06/Levente-Meszaros.jpg |
After completing his PhD at King’s College London, Levente worked as a postdoctoral fellow in radiopharmaceutical development. In 2018 he joined NanoMab Technology Limited first in Shanghai then in London, supporting two early phase 1 diagnostic trials in China and Germany and a phase 2 diagnostic trial in the UK. Levente joined Radiopharm Theranostics (RAD) in September 2021 where he is currently Vice President, Preclinical and Translational Science. He also coordinates R&D activities at Radiopharm Ventures, a joint venture with the MD Anderson Cancer Center. RAD currently has six active clinical trials in the USA and Australia. |
|
|
Liliana |
|
Greger |
|
Senior Director of Bioinformatics |
Amphista Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/10/Liliana-Greger.jpg |
|
|
|
Markus |
|
Queisser |
|
Scientific Director |
GSK |
https://proventainternational.com/wp-content/uploads/2024/07/Markus-Queisser.jpg |
Markus Queisser, PhD, is Scientific Director at GSK, where he leads work in targeted protein degradation (TPD) and induced proximity modalities. With over 15 years of experience spanning PROTACs, molecular glues, and degraderantibody conjugates (DACs), recognised voice in the field, with a strong publication record. He serves on the Steering Committee at ProxiDrugs and chairs the SLAS Special Interest Group on Proximity Assays. Markus will facilitate the Chemical Biology, Targeted Protein Degradation & Undruggables track at this year’s meeting. |
|
|
Miraz |
|
Rahman |
|
Chief Technology Officer |
Aethox Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/07/Untitled-design-3.png |
Miraz Rahman is a Professor of Medicinal Chemistry at King’s College London, with extensive expertise in both early- and late-stage drug discovery. He graduated as a pharmacist from the Faculty of Pharmacy at the University of Dhaka, Bangladesh, in 1996. After three years in the industry, he transitioned to academia, completed his PhD in synthetic medicinal chemistry at the London School of Pharmacy (now UCL School of Pharmacy), and worked as a CRUK Research Fellow for three years. In 2012, he joined King’s College London as a Lecturer and was subsequently promoted to Chair in Medicinal Chemistry in 2021. He is currently Head of the Drug Discovery Research Division at King’s College London. Miraz is committed to translating innovative laboratory research into commercialization and patient care. He holds 20 patents as an inventor and has co-founded several university spin-out companies, including Pheon Therapeutics, a clinical-stage company developing first-in-class antibody-drug conjugates for the treatment of solid tumours. |
|
|
Nataly |
|
Hastings |
|
CEO |
Cellestial Health |
https://proventainternational.com/wp-content/uploads/2026/09/Nathaly-Hastings.jpg |
|
|
|
Nicolas |
|
Triballeau, Ph.D |
|
Director Drug Discovery – Chemistry |
Revvity Signals |
https://proventainternational.com/wp-content/uploads/2025/03/Nicolas-Triballeau.jpg |
Nicolas Triballeau is the Drug Discovery Chemistry Lead at Revvity Signals. With 17 years of experience in drug discovery, he has not only provided direct project support and led teams but has also played a significant role in establishing scientific standards and ontologies. Nicolas holds a master’s degree in chemical engineering with a specialization in organic chemistry, a Pharm.D. and a Ph.D. in Drug Design from the University of Paris. |
|
|
Romuald |
|
Laine |
|
Head of R&D Evaluation and Partnering |
Servier Pharma |
https://proventainternational.com/wp-content/uploads/2026/08/Romuald-Laine.jpg |
|
|
|
Shiva |
|
NickAria |
|
CEO and Founder |
Aria Therapeutics |
https://proventainternational.com/wp-content/uploads/2026/10/Shiva-NickAria.jpg |
|
|
|
Steven |
|
Howard |
|
Director |
Astex Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2026/08/Steven-Howard.jpg |
Steven Howard is a senior member of the medicinal chemistry team at Astex Pharmaceuticals in Cambridge, UK. He has extensive experience in fragment-based drug discovery across multiple target classes in oncology and neurology. His particular areas of interest include structure-based drug design and the application of new chemical technologies to the synthesis of biologically active molecules. Steven has contributed to a number of successful projects that havedelivered clinical candidates, including the XIAP antagonist ASTX660, the MDM2 ant |
|
|
Steven |
|
Zimmer |
|
CEO |
Dark Matter Therapeutics |
https://proventainternational.com/wp-content/uploads/2020/03/Steven-Zimmer-1.jpg |
Steven Zimmer is a biotechnology executive and strategic advisor working at the intersection of AI-driven drug discovery and longevity medicine. As CEO of Dark Matter Therapeutics (Watertown, MA), he leads an AI platform advancing programs in Opioid use disorder, neurodegenerative diseases and Kidney Fibrosis, including an NIH-funded collaboration with Hunter College/CUNY. He is also Co-founder, Director, and Strategic Advisor of Cortesi Longevity, a London-based private longevity advisory serving ultra-high-net-worth clients. His expertise spans AGE-RAGE biology, glycan and epigenetic aging biomarkers, and translational neuroscience. Based in Oxford, UK, Steven works closely with founders, scientists, and investors to build early-stage life sciences ventures. He is a trained Biochemist/Molecular Biologist and spent 20 years on Wall Street and the City of London as an analyst, investment banker and portfolio manager. |
|
|
Tom |
|
Diethe |
|
Executive Director, Head of the Centre for Artificial Intelligence |
AstraZeneca |
https://proventainternational.com/wp-content/uploads/2026/06/Tom-Diethe.jpg |
|
|
|
Zev |
|
Wisotsky |
|
Director, Drug Discovery Biologics |
Revvity Signals |
https://proventainternational.com/wp-content/uploads/2024/04/Zev-Wisotsky.jpg |
Zev earned his B.A. in Molecular and Cellular Biology from UC Santa Cruz and a Ph.D. in Neuroscience from UC Riverside, where he studied taste detection in fruit flies. After transitioning from academia, he joined early-stage startups to help streamline scientific processes. Drawing on deep experience at the intersection of science and technology, Zev now serves as Director, Discovery Biology Solutions at Revvity Signals, where he focuses on tailoring software solutions to meet the evolving needs of the life sciences community. |